Opus Genetics secures $2 million funding for MERTK program to develop gene therapies for retinitis pigmentosa.
ByAinvest
Saturday, Jun 21, 2025 8:08 am ET1min read
CYCC--
MMM--
Cyclacel Pharmaceuticals has announced a $3M securities purchase agreement with accredited investors to raise funds for general corporate purposes. The transaction includes warrants for common stock and is expected to extend the company's cash runway into Q3 2025. Analysts have given a mixed outlook on the stock, with a Buy rating and a $11.00 price target. However, the company's low financial performance score and negative P/E ratio make its valuation unattractive.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet